NCT06764797 Investigating the Efficacy of Combining Virtual Reality-Based Mirror Therapy (VRMT) and Transcranial Direct Current Stimulation (tDCS) to Improve Upper Limb Recovery in Patients with Stroke
| NCT ID | NCT06764797 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | King Saud University |
| Condition | Stroke Rehabilitaion |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-09-19 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 300 participants in total. It began in 2023-09-19 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate whether combining virtual reality-based mirror therapy (VRMT) and transcranial direct current stimulation (tDCS) alongside conventional physical therapy (CPT) will significantly improve hand function for patients with stroke compared to using VRMT or tDCS alone.
Eligibility Criteria
Inclusion Criteria: * At least 18 years old. * Stroke patients with unilateral cerebral infarction or hemorrhage, more than three months following the stroke. * Adequate cognitive ability to follow instructions (The Arabic version of the Mini-Mental State Examination scores \> 24). * Modified Ashworth scale score \< 3. * Fugl-Meyer Assessment (FMA) score of 10-58 indicating moderate-to-severe arm impairment. Exclusion Criteria: * visual impairment and field defect or hemi-sensory inattention and unilateral neglect. * Wernicke's aphasia, or global aphasia, leads to difficulty following instructions. * Any contraindication to NIBS. * Other neurological conditions or participation in another study.
Contact & Investigator
Alaa M. Albishi, Doctor of Philosophy
PRINCIPAL INVESTIGATOR
King Saud University
Frequently Asked Questions
Who can join the NCT06764797 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke Rehabilitaion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06764797 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 300 participants.
Is NCT06764797 currently recruiting?
Yes, NCT06764797 is actively recruiting participants. Contact the research team at aalbeshi@ksu.edu.sa for enrollment information.
Where is the NCT06764797 trial being conducted?
This trial is being conducted at Riyadh, Saudi Arabia, Riyadh, Saudi Arabia.
Who is sponsoring the NCT06764797 clinical trial?
NCT06764797 is sponsored by King Saud University. The principal investigator is Alaa M. Albishi, Doctor of Philosophy at King Saud University. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.